,
Myeloma Investment Fund

Coming – January 22

Accelerating a Cure for Multiple Myeloma

Date and Time

January 22

–

4:00 PM ET / 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

The Myeloma Investment Fund, an arm of the Multiple Myeloma Research Foundation, is a philanthropic venture fund working toward a cure for multiple myeloma. They’re on a mission to accelerate new therapies by engaging the venture community to create a self sustaining fund that re-invests all returns to support myeloma research and treatment development.

The Myeloma Investment Fund is part of the new wave of venture philanthropy that bridges the funding and strategic gap at early stages of drug development. Investing in the most promising private biotech companies enables the Myeloma Investment Fund to:
  • Advocate for myeloma patients to potentially benefit from the most advanced therapeutic technologies in development
  • Provide strategic guidance to portfolio companies to maximize the probability of success of their myeloma programs
  • Benefit from the potential of financial returns that can create a sustainable funding source to support our mission

Multiple myeloma is a blood cancer that develops in plasma cells in bone marrow, the soft, spongy tissue at the center of your bones. In healthy bone marrow, normal plasma cells make antibodies to protect your body from infection. In multiple myeloma, plasma cells are transformed into cancerous cells that grow out of control, crowding out the normal cells that help fight infection. It can lead to anemia, kidney failure, bone damage, and more.

Please join this Force For Good fireside chat with Dr. Stephanie Oestreich, Managing Director, Myeloma Investment Fund, to hear how you can help join the fight against this debilitating disease.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.